Wednesday, October 24th, 4:30-5:30pm
China is actively investing in biotechnology development through many different avenues. Hear a panel of experts explain the advantages of operating in China and engaging in cross-border collaborations, and learn how Chinese and Western biopharma companies can gain access to meaningful capital.
Moderator:
- TBD
Panelist:
- Samantha Du, PhD, Managing Director, Sequoia Capital
- Alan Hu, Healthcare Fund Partner, Deloitte
- Dan Junguo, PhD, Chendgu University of Traditional Chinese Medicine
- Sun Wansong, PhD, Director of Investment Promotion, Secretary of the CPC, Clinical Medicine, Ministry of Commerce, People's Republic of China
- Yu Yanfei, Section Chief, Fudding Construction Section of Bio City of Wu Han Guang Gu Cluster
Who's Who
|
Sun Wansong, PhD Dr. Sun Wansong serves as Director of the Project Operation Department of the China Investment Promotion Agency at the Ministry of Commerce. He holds a Doctoral degree in Management, and finished his post-doctoral research at Tsinghua University. Dr. Sun‘s research has focused on the innovation and development of industrial parks. He has published four books, including Self-Innovation and Core Competence in High-Tech Zones, and over 20 academic papers in national top-level journals and international conferences. Dr. Sun has won several provincial and national Social Science Outstanding Achievement Awards and Technological Progress Awards. |